Logotype for Organo Corporation

Organo (6368) Q2 2025 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Organo Corporation

Q2 2025 earnings summary

3 Oct, 2025

Executive summary

  • Orders received in the first half rose 21.8% year-over-year to ¥92.8 billion, with strong growth in overseas large-scale electronics projects, especially in Taiwan and China.

  • Net sales increased 13.5% year-over-year to ¥74.3 billion, driven by robust performance in Plant and Service Solutions, particularly overseas.

  • Operating profit surged 46.1% year-over-year to ¥11.5 billion, with profit margin improvement in both Plant and Service Solutions.

  • Profit attributable to owners of parent rose 46.9% YoY to ¥8.1 billion.

  • The company executed digital transformation initiatives and expanded production and delivery capacities.

Financial highlights

  • Gross profit for the first half reached ¥23.1 billion (+27.7% YoY), with gross margin improving to 31.1%.

  • SG&A expenses increased 13.5% YoY to ¥11.7 billion, but were offset by higher profit margins.

  • Basic earnings per share: ¥176.97 (up from ¥120.64 YoY).

  • Comprehensive income: ¥9,050 million (+36.8% YoY).

  • Total assets: ¥180,814 million; Net assets: ¥108,490 million; Equity-to-asset ratio: 59.9%.

Outlook and guidance

  • Full-year forecasts were revised upward, with orders expected at ¥170 billion (+17.7% YoY), net sales at ¥165 billion (+9.7% YoY), and operating profit at ¥28 billion (+24.2% YoY).

  • Profit attributable to owners of parent for the full year is forecast at ¥21.5 billion (+24.2% YoY).

  • Dividend forecast for FY03/2025 was raised to ¥142 per share, maintaining a payout ratio above 30%.

  • Full-year ROE is forecast at 19.6%, up 1.2 points year-over-year.

  • Orders and sales are expected to remain strong in the second half, especially for large-scale semiconductor projects overseas.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Organo